Presentation Description: There are no approved therapies to treat chronic pulmonary S. aureus (including MRSA) in CF, which affects approximately 25% of patients and results in shortened life expectancy. We are developing a lipoglycopeptide (RV94) therapy as an inhaled dry powder for once daily dosing, effective against bacteria in planktonic, intracellular, and biofilm stores, the latter of which have been linked to clinical relapse. A median MRSA MIC (12 isolates) for RV94 was 0.015 μg/mL, making it 60-fold more potent than vancomycin and 2-4-fold more potent than the lipoglycopeptides oritavancin and telavancin. RV94 demonstrated superior MRSA killing intracellularly which was 4-6-fold more potent than vancomycin, linezolid, and tigecycline. Against standard MRSA biofilms, RV94 was 10-fold more potent than vancomycin. When administered prophylactically and therapeutically in an acute efficacy model in rats, a single inhaled dose of RV94 demonstrated a statistically significant reduction in bacterial lung burden versus the control.
Understand the unmet need for the development of novel inhaled formulations to treat resistant Staphylococcal aureus infections in cystic fibrosis patients.
Understand the recent advancements in inhaled formulation technologies to treat lung infections.
Raise awareness of the preclinical animal models to evaluate formulations to treat lung infections.